Trevena to Report First Quarter 2018 Financial Results on May 3, 2018

CHESTERBROOK, Pa., April 26, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review financial results for the quarter ended March 31, 2018 and to discuss recent corporate highlights.

To join the call, please dial-in at (855) 465-0180 (conference ID: 1350009).

To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 1350009). Following the conclusion of the call, the webcast will be available for replay for 30 days.

About Trevena

Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain.  The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain.  Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications. 

Contacts

Trevena, Inc.

Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]

or

Media:
Public Relations
[email protected]